HKeyBio Launches First NHP In Vitro Model for Autoimmune and Allergic Diseases — HKeyBio

Event summary

HKeyBio launched HKEY-NHP-onChip™ 1.1, the world's first non-human primate (NHP) in vitro model system for autoimmune and allergic diseases.
The platform integrates NHP-derived organoids, organ-on-chip technologies, and immune–tissue co-culture systems, reducing single-experiment costs by 10–100× and animal use by 60–80%.
The platform covers 12 diseases, including asthma, COPD, atopic dermatitis, psoriasis, inflammatory bowel disease, rheumatoid arthritis, and multiple sclerosis.
HKeyBio aims to transform from an NHP in vivo model expert to an integrated in vivo–in vitro research platform.

The big picture

HKeyBio's launch of HKEY-NHP-onChip™ 1.1 addresses a critical gap in preclinical research for autoimmune and allergic diseases, offering a cost-effective and ethically superior alternative to traditional in vivo models. The platform's ability to reduce variability and increase predictive accuracy positions it as a strategic asset in a market projected to grow to $218 billion by 2030. The integration of NHP-derived models with organ-on-chip technologies represents a significant shift in the CRO landscape, potentially setting a new standard for translational research.

What we're watching

Market Adoption: How quickly biotech and pharmaceutical companies will adopt HKEY-NHP-onChip™ 1.1 for their drug development processes.
Technological Advancements: The pace at which HKeyBio can integrate AI predictive models for efficacy and toxicity into its platform.
Regulatory Acceptance: Whether regulatory bodies will recognize and accept data generated from HKEY-NHP-onChip™ 1.1 as sufficient for clinical trial approvals.